Popular Articles

Leicester Geneticists Unearth The Roots Of Human Genetic Variation
A new study at the University of Leicester is using advanced single molecule methods to explore processes that lie at the very core of DNA variation in humans.
diet pills
NMC Statement Re Gosport War Memorial Hospital
The Nursing & Midwifery Council (NMC) is extremely concerned about the length of time that it is taking to resolve the issues for the families of former patients at Gosport War Memorial Hospital.
News of the day
Obama Says He Is 'Absolutely Committed' To Health Reform
During a C-SPAN interview on Saturday, President Obama said he remains "absolutely committed" to overhauling the U.S. health care system despite obstacles that might surface during reform efforts, the Los Angeles Times reports (Dorning, Los Angeles Times, 5/24). He said he would work to keep "this process moving, ... focusing on how we reduce costs, how do we make sure families have some confidence that they can get health care when they need it and they won"t go bankrupt because their child gets sick" (Adams Otis, New York Post, 5/24).Obama said that his health care plan would provide "basic coverage" to all U.S. residents and retain patient choice of physicians and coverage. In addition, he said his plan would "invest more in prevention and wellness programs," as well as increase the use of electronic health records (Rushing, The Hill, 5/23).Obama also said that refusing to address the rising costs of Medicaid and Medicare now means the U.S. will face a bigger financial crisis in the future. He said overhauling health care would reduce costs and free up additional funding over the long term. This would make it easier to pay down the $11 trillion national debt and manage other financial issues, Obama said (New York Post, 5/24).Because such rising costs have shifted the political climate, Obama said that he believes "the stars may be aligned" for reform and that he can succeed where former President Clinton failed. Obama said, "The biggest change politically ... is that businesses now recognize that if we don"t get a handle on this stuff that they are going to continue to be operating at a competitive disadvantage with other countries." He added, "And so they anxiously seek serious reform" (Los Angeles Times, 5/24).
Nutrition

Early Switch From Cyclosporine To Sirolimus After Renal Transplantation Produces Sustained Improvement In Renal Function

BOSTON - Favorable 12-month outcomes are maintained through 30 months of follow-up when renal transplant patients are converted from a cyclosporine (CsA)-based regimen to a sirolimus (SRL)-based regimen three months post-transplant, according to results of the CONCEPT study announced here at the American Transplant Congress (ATC) 2009. Yvon Lebranchu, MD, from the University FranÃýois Rabelais in Tours, France, reported 30-month results in patients who were initially treated with mycophenolate mofetil (MMF) plus cyclosporine (CsA) and then randomized three months later to continue this regimen, or CsA therapy was stopped and replaced by SRL. The trial included 192 first-time renal allograft recipients at 16 centers throughout France. "Long term use of CsA may contribute to the development of chronic allograft nephropathy," Dr. Lebranchu pointed out. "While earlier trials have demonstrated a positive impact of de novo SRL on renal function at one year post transplantation, adverse effects have limited the use of this approach." An analysis at 12 months in 181 patients found that glomerular filtration rate (GFR), as estimated by the simplified MDRD formula, was significantly better in the SRL group (61.9 mL/min versus 53.8 mL/min, p=0.0002). Improvement in renal function occurred without a significant increase in acute rejection. Thirty-month results in 152 patients in the intent-to-treat population showed an MDRD GFR of 58.3 mL/min and 52.6 mL/min in the two groups, respectively, p=0.027. This difference was more pronounced in patients on treatment: 64.4 mL/min and 53.8 mL/min in the two groups, respectively. Graft loss and patient survival were similar in the two treatment groups. One patient in the SRL/MMF group had developed a malignancy versus six patients in the CsA group. "Long-term maintenance of renal function is a challenge in renal transplant recipients, and the use of CNIs is associated with chronic long-term graft dysfunction," Dr. Lebranchu said. "The identification of strategies of CNI avoidance or elimination is extremely important." Sandi See Tai, MD, Director, Global Medical Affairs, Transplantation, Wyeth Pharmaceuticals, said that the data are encouraging "because they indicate better long-term outcomes for kidney transplant patients." Wyeth Pharmaceuticals markets sirolimus under the trade name RAPAMUNE®. "Overall, the interim results of CONCEPT show that a sirolimus-based regimen may provide lasting benefits in renal transplant patients," Dr. Lebranchu added. Written by Jill Stein Jill Stein is a Paris-based freelance medical writer. jillstein03(at)gmail.com Copyright: Medical News Today Not to be reproduced without permission of Medical News Today


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):